RESULTS: Among 1,290 patients with available data, 585 (45%) and 284 (22%) men had any PCa and significant PCa, respectively. PSA density was significantly more predictive than PSA for detecting any and significant PCa in the PSA ranges of 4-10 and >10 ng/mL. AUC for significant prostate cancer was 0.72 (0.68, 0.77), p<0.0001 for PSA 4-10 ng/mL and 0.82 (0.75, 0.89), p<0.0001 for PSA >10 ng/mL. PSA density was significantly more predictive than PSA in detecting any and significant PCa in men with and without a prior negative biopsy. However, the incremental AUC value was larger for significant PCA than any PCA in men who had a prior negative prostate biopsy (AUC 0.81 vs 0.70, p ¼ 0.0042), and those who did not (AUC 0.77 vs 0.73, p ¼ 0.0026).
INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) screening with prostate-specific antigen (PSA) reduces PCa mortality, but leads to overdiagnosis of indolent PCa. Use of 5-alpha reductase inhibitors (5-ARIs) lowers PSA and in theory could affect performance of PSA-based screening. We evaluated outcomes of PCa screening among 5-ARI users.
METHODS: The study was performed within the Finnish Randomized Study of Screening for Prostate Cancer. Of 80,454 men, 31,866 were randomized to be screened at four-year intervals during 1996-2004. Information on 5-ARI reimbursements before PCa during 1995-2009 was collected from the national prescription database for 78,615 men. We evaluated the effect of screening on PCa risk and mortality by 5-ARI usage using Cox regression. RESULTS: Men using 5-ARIs had higher median PSA and were more often screen-positive compared to non-users. Despite this, screening did not significantly affect PCa detection (HR 0.89, 95% CI 0.79-1.01) or mortality (HR 0.82, 95% CI 0.51-1.32) compared to the control arm among 5-ARI users. In ROC analysis, PSA and age did not predict Gleason 7-10 prostate cancer as accurately in 5-ARI users as among the non-users (AUC ¼ 0.88 versus 0.79 in the first screening round).
CONCLUSIONS: PSA-based screening among men using 5-ARIs does not improve detection of high-grade or metastatic PCa or prevention of PCa deaths. Targeted screening should focus on men not using 5-ARIs. So Ushijima, Koji Okihara*, Koji Kitamura, Kazumi Kamoi, Osamu Ukimura, Kyoto, Japan INTRODUCTION AND OBJECTIVES: There have recently been a number of reports on predictors for a positive repeat prostate biopsy in patients on an outpatient-referral basis. On PSA prostate prostate cancer screening, unlike outpatient referral basis, a clarification to select screened patients for repeat biopsy needs to be balanced by cost and survival benefit. For this purpose, a validation of the screening system and its modification, if necessary, are extremely important. The aim of this study is to assess possible predictors in determining criteria for repeat biopsy in a prostate cancer screening population.
METHODS: A total of 93553 men over 55 years-of-age have participated in a prostate cancer screening program in Otokuni district, Kyoto, Japan for 21 years. Transperineal systematic biopsy with 8-12 cores was carried out in the cases of positive digital rectal examination (DRE) or positive transrectal ultrasonography (TRUS) or a prostate specific antigen (PSA) value greater than 10.0 ng/mL. For those with a PSA level from 4.1 to 10.0ng/mL, and negative DRE and TRUS findings, biopsy was indicated only when PSA density (PSAD) was greater than 0.15. The same indication was applied for the repeat biopsy.
RESULTS: A repeat biopsy after an interval of more than 1 years was carried out in 401 patients and was positive in 167 (41.6%) patients. The PSA value at the diagnosis of cancer declined from the initial value in 26 men (15.6%). The assessment parameters are as follows: age at the final biopsy, change of PSA value, PSA velocity, DRE finding and PSAD value at the latest screening. In multivariate analysis, age, PSAD and positive DRE finding are independent parameter in predicting positive repeat biopsy. The odds ratio in Age>72, PSA>0.30 and positive DRE are 1.86 (1.18 -2.96), 3.91 (2.47 -6.24), 2.35(1.09 -5.25), respectively. Of those 3 parameters, when repeat biopsy definition is determined in either positive of 3 parameters, unnecessary biopsy can be decreased in 17.0 %, while localized cancer with low risk group will be missed in 10.1%.
CONCLUSIONS: A decrease in the repeated PSA value cannot predict a negative biopsy outcome under the consecutive and established biopsy criteria. The combination of these three parameters (age, positive DRE and PSAD) might help to reduce unnecessary repeat biopsies in the high-risk cohort of patients with negative initial biopsies.
Source of Funding: None.
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DETERMINANTS OF DEFAULT FROM FOLLOW-UP CARE IN A PROSTATE CANCER SCREENING PROGRAM
Mark Ferretti*, New York, NY; Michael Goltzman, Akhil Saji, Neel Patel, Denton Allman, Sean Fullerton, Gerald Matthews, John Phillips, Valhalla, NY INTRODUCTION AND OBJECTIVES: The curability of highrisk prostate cancer (PCa) may depend on early diagnosis and compliance with management modalities. Delayed or incomplete treatment for PCa may result in inferior clinical outcomes and lower survival rates. We sought to identify the proportion of and predictors of loss of follow-up care after positive prostate biopsy in a single-institution, retrospective cohort study METHODS: Patients who did not follow up for or so-called 'defaulted' treatment were defined as those who had failed to return for treatment or follow-up discussion after diagnosis of PCa. This did not include patients who elected to be treated at other hospitals. Demographic and clinical characteristics, were compared between defaulters and non-defaulters. A multiple linear regression was performed to predict those individuals likely to default.
RESULTS: From October 2008 to April 2013, 6182 patients received 12,930 PSA tests at a single institution. Of these patients, 574 (9%) patients had at least one PSA test level greater than 4 ng/mL. A total of 210 patients had subsequent biopsy, of which 141 had a PSA test >4 ng/mL. PCa was detected in 85 (41%) patients, of which 17 (20%) patients failed to follow up. The majority (88%) of defaulters were made aware of their biopsy results prior to self-cessation of care. Defaulters were significantly younger (61.8 AE 2.0y) at time of biopsy compared to non-defaulters (65.8 AE 1.0y), t(83) ¼ 1.8, p ¼ 0.04. Those individuals with an unspecified primary care provider (65%) were more likely to default than those who had primary care doctor at our institution (p<.001). Defaulters were more likely to be uninsured (24%) as compared to those with continued care (4%) (p¼.01). Defaulters were more likely to Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e751
